Trexquant Investment LP - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
Trexquant Investment LP ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$1,053,386
-20.9%
29,548
+2.3%
0.03%
-25.7%
Q2 2023$1,332,234
+37.4%
28,880
+19.5%
0.04%
+29.6%
Q1 2023$969,337
-52.5%
24,173
-45.1%
0.03%
-53.4%
Q4 2022$2,038,844
+102.7%
44,007
+81.1%
0.06%
+65.7%
Q3 2022$1,006,000
-23.3%
24,304
+10.5%
0.04%
-40.7%
Q2 2022$1,312,000
+48.9%
21,988
+81.2%
0.06%
+43.9%
Q1 2022$881,000
+0.7%
12,135
+32.3%
0.04%
-44.6%
Q2 2021$875,000
+107.8%
9,175
+79.2%
0.07%
+174.1%
Q3 2020$421,000
-52.8%
5,120
-55.1%
0.03%
-56.5%
Q2 2020$892,000
+131.7%
11,399
+88.0%
0.06%
+77.1%
Q2 2019$385,000
-25.2%
6,062
-48.9%
0.04%
+9.4%
Q4 2018$515,000
-50.9%
11,852
-13.1%
0.03%
-56.2%
Q2 2018$1,049,000
+314.6%
13,645
+279.0%
0.07%
+82.5%
Q4 2016$253,000
-47.5%
3,600
-47.1%
0.04%
-63.0%
Q3 2016$482,000
-71.2%
6,800
-80.2%
0.11%
-50.9%
Q2 2016$1,676,000
+547.1%
34,265
+736.3%
0.22%
+633.3%
Q1 2016$259,000
-74.4%
4,097
-54.5%
0.03%
-66.3%
Q4 2015$1,010,000
+49.6%
9,000
-41.6%
0.09%
-25.2%
Q4 2014$675,00015,4000.12%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2022
NameSharesValueWeighting ↓
Iguana Healthcare Management, LLC 75,000$4,658,0002.63%
COLUMBIA WANGER ASSET MANAGEMENT LLC 1,364,434$84,745,0001.21%
CAPITAL INTERNATIONAL LTD /CA/ 259,700$16,130,0001.07%
Aureus Asset Management, LLC 65,670$4,079,0000.69%
Capital International Sarl 124,320$7,722,0000.67%
CAPITAL GUARDIAN TRUST CO 512,430$31,827,0000.58%
ROCKEFELLER FINANCIAL SERVICES INC 408,379$25,365,0000.50%
Rock Springs Capital Management LP 160,500$9,969,0000.50%
Hood River Capital Management LLC 112,296$6,975,0000.48%
Capital International, Inc./CA/ 52,700$3,273,0000.47%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders